The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10509 malaria professionals are enjoying the free benefits of MalariaWorld today

relapse

NOT Open Access | Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis

February 14, 2020 - 16:59 -- NOT Open Access
Author(s): 
Anjum MU, Naveed AK, Mahmood SN, Naveed OK
Reference: 
Travel Med Infect Dis. 2020 Feb 6:101576

Plasmodium vivax is a frequent cause of recurring malaria in endemic areas as in its latent stage it resides in liver, and is responsible for relapse.

Treatment with 8 aminoquinoline Primaquine is given for 14 days, however studies have shown dismal results with adherence to therapy. A new long acting 8 aminoquinoline, Tafenoquine was introduced that showed efficacy and safety almost similar to Primaquine in a single dose regimen, hence giving hopes for improved compliance and help in eradicating malaria.

Subscribe to RSS - relapse